One Step Closer to a Cure: Breakthrough “Harmine Pill” Sparks Hope for 500 Million Diabetics Worldwide
Mount Sinai researchers discovered that harmine, a beta cell regenerative drug, may transform alpha cells into beta cells, ...
Why Is Beam Therapeutics Inc. (BEAM) Among the Top CRISPR Stocks to Invest In?
We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where ...
Gubra and Amylyx team on novel long-acting GLP-1 receptor antagonist development
Pharmaceuticals for the development of a potential. “We are pleased to partner with Amylyx to advance GLP-1 receptor antagonism research. This collaboration and development agreement is an example of ...
Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip
The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives $47.67 Average PT from Analysts
Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) has earned a consensus rating of “Moderate Buy” from the eleven analysts that are covering the stock, Marketbeat Ratings reports. Three ...
Krystal Biotech: Blockbuster Ambitions For Topical Gene Therapy
Krystal Biotech's VYJUVEK, a groundbreaking gene therapy for DEB, achieved $83.8M in Q3 2024 sales. Read why I rate KRYS ...